"Undiagnosed Mild Cognitive Impairment: A Growing Concern"

Two recent studies reveal that mild cognitive impairment, an early stage of dementia, is significantly underdiagnosed in people aged 65 and older, with only 8% of expected cases being diagnosed. This underdiagnosis deprives millions of patients of the opportunity to receive treatment and slow disease progression. Mild cognitive impairment can be caused by various factors, including medication side effects and vitamin deficiencies, and shares risk factors with cardiovascular disease. The FDA has approved lecanemab as the first disease-modifying treatment for Alzheimer's disease, which can reduce the progression of early-stage Alzheimer's. However, these drugs must be used in the early stages of the disease. Factors contributing to underdiagnosis include subtle symptoms and limited time during doctor's visits. Vigilance about cognitive decline and formal assessments are crucial, and utilizing Medicare's yearly "wellness" visit is recommended.